Endocannabinoids and Liver Disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases
Endocannabinoids and Liver Disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases
复制标题
DOI：
10.1152/ajpgi.00523.2007
复制
发表时间：
2008-04-01
影响因子：
4.5
通讯作者：
Gao, Bin
中科院分区：
文献类型：
--
作者：
Pacher, Pal;Gao, Bin
最近的研究表明，内源性大麻素系统在各种肝脏疾病及其并发症中调节失调（例如，例如，在一个实施例中，肝炎、纤维化、肝硬化、缺血性心肌病和缺血-再灌注），并证明大麻素2（CB 2）受体激动剂或CB 1拮抗剂对其的调节可能具有显著的治疗益处。这篇综述的目的是关注肝脏炎症过程中内源性大麻素的触发因素和来源，以及CB 2受体在激活的内皮细胞和各种炎症细胞（白细胞，淋巴细胞等）之间相互作用中的新作用，其在炎性和其它肝脏疾病的早期发展和进展中起关键作用。
Recent studies have implicated dysregulation of the endocannabinoid system in various liver diseases and their complications ( e. g., hepatitis, fibrosis, cirrhosis, cirrhotic cardiomyopathy, and ischemia-reperfusion), and demonstrated that its modulation by either cannabinoid 2 (CB2) receptor agonists or CB1 antagonists may be of significant therapeutic benefits. This review is aimed to focus on the triggers and sources of endocannabinoids during liver inflammation and on the novel role of CB2 receptors in the interplay between the activated endothelium and various inflammatory cells ( leukocytes, lymphocytes, etc.), which play pivotal role in the early development and progression of inflammatory and other liver diseases.